pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

PATH

updated 5mo ago
community read0 votes

🐶 often sniffed alongside

top 8
  • tagRecall10 co-mentions · 10 sources
  • tagHematology6 co-mentions · 6 sources
  • tagAdCom4 co-mentions · 4 sources
  • tag510(k) Clearance3 co-mentions · 3 sources
  • companyUniversity of Virginia1 co-mentions · 1 sources
  • companyUniversity of Washington1 co-mentions · 1 sources
  • tagCardiology1 co-mentions · 1 sources
  • tagImmunology1 co-mentions · 1 sources
pipeline
1
marketed
0
phase 3
0
catalysts ytd
8
approvals ytd
0
recalls ytd
6

Pipeline(1)

pipeline depth1 products
Preclinical: 1
1Preclinical
Preclinical
Anti-CSP Monoclonal Antibody
Malaria

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • phase2Study of a Novel Type 1 Oral Poliomyelitis Vaccine in Bangladeshcompletedn=2,232
  • phase2Study of a Novel Type 3 Oral Poliomyelitis Vaccine in Panamarecruitingn=1,532
  • phase2Study of Co-administered (Types 1 & 2) Novel Oral Poliomyelitis Vaccines Evaluationrecruitingn=675
  • phase2Infant Malaria Vaccine Schedule Optimizationrecruitingn=1,200
  • phase3Phase 3 Trial of a Bivalent Human Papilloma Virus (HPV) Vaccine (Cecolin®) in Young Girlscompletedn=1,025
  • phase1Study of Novel Types 1 and 3 Oral Poliomyelitis Vaccinescompletedn=226
  • phase2Study of Malaria Vaccine RTS,S/AS01E in Plasmodium Falciparum-infected and Uninfected Adults Pre-treated With Anti-malarial Therapycompletedn=620
🐶 Hiring Signal
No open roles indexed yet — view PATH jobs →

News

  • Actinogen’s sole drug fails pivotal Alzheimer’s study, sinking stock 80%
    Actinogen Medical’s lead program for its sole pipeline candidate has failed a late-stage study, but the Australian biotech still plans on taking the findings to the FDA for a path forward.
    biospace · 5h ago
  • nChroma halves workforce, BioXcel lets execs go
    Follow along as BioSpace tracks job cuts and restructuring initiatives.
    biospace · 5h ago
  • With FDA nod, Regeneron brings an RNAi drug to autoimmune disease
    The product of a collaboration with Alnylam, Livsayis is now Regeneron’s first marketed RNAi drug and will compete against established medicines from AstraZeneca and Argenx.
    biopharma_dive · 6h ago
  • nChroma halves headcount, calls time on trial of potential HBV ‘cure’
    nChroma Bio’s workforce is facing a second round of layoffs in 12 months, with the Boston biotech halving its headcount and scrapping a trial of its lead hepatitis asset.
    fiercebiotech · 12h ago
  • CTAD 2026: Biogen, AriBio lead the way in slowing cognitive decline in Alzheimer’s
    Biogen and AriBio reported wins for their respective therapies targeting Alzheimer’s disease, while Priavoid and Cognito Therapeutics missed the mark—though the latter plans to file for FDA approva…
    biospace · 1d ago
  • FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSK
    The FDA had several issues with ivonescimab, according to the letter. Elsewhere, Sellas shares rocketed on results for a leukemia vaccine and Biogen and Lilly struck up new R&D pacts.
    biopharma_dive · 1d ago
  • In China’s shadow, Pfizer CEO calls for AI savings to bolster Big Pharma
    Speaking at the Jefferies conference in London, Pfizer CEO Albert Bourla warned of China’s rise and spoke to how companies like his can compete by leveraging AI-discovered savings.
    biospace · 1d ago
  • AbbVie busts a move with Disco in $2.5B dance aimed at bispecific discovery
    AbbVie is twirling onto the dance floor with Disco Pharmaceuticals, offering up to $2.5 billion to work with the German platform company on cancer-targeted bispecific discovery.
    fiercebiotech · 1d ago
  • Cognito phase 3 flops in light-and-sound Alzheimer's trial, but sees ‘signal’ for HOPE
    Cognito Therapeutics said its phase 3 HOPE study of Spectris AD, an investigational, non-invasive, at-home Alzheimer's therapy that uses light and sound stimulation to engage brain activity, failed…
    fiercebiotech · 1d ago
  • Beren wins FDA approval for long-studied rare disease drug
    A molecule designed by government scientists more than a decade ago has won FDA approval to treat infantile-onset Niemann-Pick disease type C, capping a winding and rocky development path. Beren Th…
    endpoints · 2d ago
view all news mentions →
identifiers
source
globaldata
top tags
Infectious Disease1
mentioned in
10news items
entity-linker matched
Data sources
openFDA
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?